

**Amendments to the Claims**

This listing of claims will replace all prior versions and listings of claims in the application:

**Listing of Claims:**

1. (Currently amended) A composition comprising an antisense oligonucleotide oligonucleotides directed against vascular endothelial growth factor (VEGF), wherein said antisense oligonucleotide is UGGCTTGAAGATGTACTCGAU (SEQ ID NO: 34).
2. (Original) The composition of Claim 1 further comprising another active agent.
3. (Currently Amended) The composition of Claim 2 wherein said active agent is a chemotherapeutic ~~such as Taxol~~.
4. (Currently Amended) The composition of Claim 1 further comprising one or more additional oligonucleotides antisense oligonucleotides, wherein said one or more additional antisense oligonucleotides are directed against vascular endothelial growth factor (VEGF) and which inhibit the proliferation of cells exhibiting autocrine VEGF activity at an IC<sub>50</sub> concentration of between about 0.5 to about 2.5 micromolar.
- 5-7. (Canceled)
8. (Original) An antisense oligonucleotide having the sequence UGGCTTGAAGATGTACTCGAU (SEQ ID NO: 34).
9. (Currently amended) A method for inhibiting cancer cell proliferation or angiogenesis, comprising ~~comprising~~ contacting said cell with an antisense oligonucleotide oligonucleotides directed against vascular endothelial growth factor (VEGF), wherein said antisense oligonucleotide is UGGCTTGAAGATGTACTCGAU (SEQ ID NO: 34).
10. (Currently amended) The method of Claim 9, wherein said cancer cell is selected from the group consisting of an ovarian cancer cell cells, a melanoma cell cells, a Kaposi's sarcoma cell cells, a prostate cancer cell cells or and a pancreatic cancer cell.

11. (Currently amended) The method of Claim 9, further comprising contacting the cancer cell with one or more additional antisense oligonucleotides directed against ~~vascular endothelial growth factor~~ (VEGF), wherein said one or more antisense oligonucleotides inhibits proliferation of cells exhibiting autocrine VEGF activity at an IC<sub>50</sub> concentration of between about 0.5 to about 2.5 micromolar.

12-13. (Canceled).

14. (Original) The method of Claim 9 wherein said antisense oligonucleotide is encapsulated in a liposome.

15.-18. (Canceled).

19. (New) The composition of claim 1, wherein said antisense oligonucleotide comprises one or more phosphorothioate linkages.

20. (New) The antisense oligonucleotide of claim 8, wherein said antisense oligonucleotide comprises one or more phosphorothioate linkages.

21. (New) The method of claim 9, wherein said antisense oligonucleotide comprises one or more phosphorothioate linkages.